Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1 participants
OBSERVATIONAL
2017-10-31
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* recent studies have demonstrated that the pathogenesis of ITP envolves multifactorial autoimmune mechanisms of both humoral and cellular immunity and that acute and chronic forms may represent two distinct immunopathological disorders ( cooper N et al 2006) ( Gern Sheimer T 2009 )
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Markers in Pediatric ITP on Second Line Therapy
NCT06093529
An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
NCT00005570
Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
NCT05093257
Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura
NCT04311593
Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.
NCT04070599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There are many phases of the disease:
1. Newly diagnosed ITP : for all cases at diagnosis.
2. persistent ITP: for patients with ITP between 3 to 12 months.
3. chronic ITP: for patients with ITP lasting more than one year ( blood journal 2009).
* Although lymphocytopenia is a commonly reported feature of many chronic autoimmune disorders, differential white cell counts at presentation have seldom been evaluated as predictors for development of chronic ITP ( Deel MD et al 2013) (Ahmed et al 2010)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
immune thrombocytopenic purpura
immune thrombocytopenic purpura an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number we used complete blood picture
complete blood picture
complete blood picture
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
complete blood picture
complete blood picture
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dolagy nabil naguib
principle investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LCITP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.